Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like Sai Life Sciences are investing heavily in capacity, anticipating a surge in demand. While regulatory processes mean benefits will be gradual, this supply-chain realignment presents a landmark opportunity for India's CDMO sector, with major players already strengthening partnerships. Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like Sai Life Sciences are investing heavily in capacity, anticipating a surge in demand. While regulatory processes mean benefits will be gradual, this supply-chain realignment presents a landmark opportunity for India's CDMO sector, with major players already strengthening partnerships. by Soban News (international And National News)
